Literature DB >> 1679392

Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine.

I Johansson1, Q Y Yue, M L Dahl, M Heim, J Säwe, L Bertilsson, U A Meyer, F Sjöqvist, M Ingelman-Sundberg.   

Abstract

The Far Eastern and Caucasian populations are strikingly different with respect to the debrisoquine/sparteine hydroxylation polymorphism. The number of poor metabolizers, as defined for Caucasians, is very low among Chinese and Japanese. We investigated the molecular basis for this difference by analysis of the CYP2D6 gene in 115 Chinese subjects, combined with phenotypic classification of codeine and debrisoquine metabolism. A correlation between the rates of metabolism of these two drugs and genotype, as analyzed by RFLP using XbaI, was observed among the Chinese. A high frequency (37%) of alleles indicative of gene insertions (reflected by XbaI 44kb fragments) was recorded in the Chinese, but was not associated with the poor metabolizer phenotype, as it is in Caucasians. PCR amplification of part of the CYP2D6 gene with mutation specific primers for CYP2D6A (29A) and CYP2D6B (29B) allelic variants revealed that the XbaI 44kb fragment in Chinese apparently contains a functional CYP2D6 gene, in contrast to the situation among Caucasians. The results provide a molecular explanation of the interethnic difference in the metabolism of drugs affected by the debrisoquine hydroxylation polymorphism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679392     DOI: 10.1007/bf00279968

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Authors:  M Heim; U A Meyer
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

2.  Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese.

Authors:  Q Y Yue; L Bertilsson; M L Dahl-Puustinen; J Säwe; F Sjöqvist; I Johansson; M Ingelman-Sundberg
Journal:  Lancet       Date:  1989-10-07       Impact factor: 79.321

3.  Evidence for polymorphic oxidation of sparteine in Japanese subjects.

Authors:  T Ishizaki; M Eichelbaum; Y Horai; K Hashimoto; K Chiba; H J Dengler
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

4.  Low frequency of slow debrisoquine hydroxylation in a native Chinese population.

Authors:  Y C Lou; L Ying; L Bertilsson; F Sjöqvist
Journal:  Lancet       Date:  1987-10-10       Impact factor: 79.321

5.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Authors:  K Nakamura; F Goto; W A Ray; C B McAllister; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

6.  Polymorphic hydroxylation of debrisoquine.

Authors:  G T Tucker; J H Silas; A O Iyun; M S Lennard; A J Smith
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

7.  Interindividual and interethnic differences in the demethylation and glucuronidation of codeine.

Authors:  Q Y Yue; J O Svensson; C Alm; F Sjöqvist; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

8.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

9.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.

Authors:  Y Horai; M Nakano; T Ishizaki; K Ishikawa; H H Zhou; B I Zhou; C L Liao; L M Zhang
Journal:  Clin Pharmacol Ther       Date:  1989-08       Impact factor: 6.875

10.  The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site.

Authors:  N Hanioka; S Kimura; U A Meyer; F J Gonzalez
Journal:  Am J Hum Genet       Date:  1990-12       Impact factor: 11.025

View more
  12 in total

Review 1.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

2.  CYP2D6 genotype determination in the Danish population.

Authors:  K Brøsen; P N Nielsen; K Brusgaard; L F Gram; K Skjødt
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

3.  Frequency of human CYP2D6 mutant alleles in a normal Chinese population.

Authors:  E J Lee; K Jeyaseelan
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

4.  Human pharmacogenomics: the development of a science.

Authors:  Werner Kalow
Journal:  Hum Genomics       Date:  2004-08       Impact factor: 4.639

5.  Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.

Authors:  C Mura; N Gerard; M Vincent-Viry; M M Galteau; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

6.  Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.

Authors:  K Weerasuriya; R L Jayakody; C A Smith; C R Wolf; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

Review 7.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

Review 8.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 9.  Pharmacogenetics: the therapeutic drug monitoring of the future?

Authors:  M H Ensom; T K Chang; P Patel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

Review 10.  The evolving role of drug metabolism in drug discovery and development.

Authors:  Lilian G Yengi; Louis Leung; John Kao
Journal:  Pharm Res       Date:  2007-03-01       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.